BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Krammer S, Krammer C, Salzer S, Bağci IS, French LE, Hartmann D. Recurrence of Pemphigus Vulgaris Under Nivolumab Therapy. Front Med (Lausanne) 2019;6:262. [PMID: 31781569 DOI: 10.3389/fmed.2019.00262] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Wirbel C, Milley S, Balme B, Dalle S. [Bullous pemphigoid under anti-PD1 therapy]. Ann Dermatol Venereol 2020;147:795-7. [PMID: 32682608 DOI: 10.1016/j.annder.2020.06.013] [Reference Citation Analysis]
2 Zhang Y, Zhang M, Xie J, Wu W, Lu J. Pemphigus Herpetiformis-Type Drug Reaction Caused by Programmed Cell Death Protein-1 Inhibitor Treatment. Clin Cosmet Investig Dermatol 2021;14:1125-9. [PMID: 34475771 DOI: 10.2147/CCID.S330354] [Reference Citation Analysis]
3 Tognetti L, Cinotti E, Suppa M, Guazzo R, Habougit C, Santi F, Diet G, Fontaine M, Berot V, Monnier J, Pianigiani E, Del Marmol V, Malvehy J, Perrot JL, Rubegni P. Line field confocal optical coherence tomography: An adjunctive tool in the diagnosis of autoimmune bullous diseases. J Biophotonics 2021;14:e202000449. [PMID: 33583143 DOI: 10.1002/jbio.202000449] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Quach HT, Johnson DB, LeBoeuf NR, Zwerner JP, Dewan AK. Cutaneous adverse events caused by immune checkpoint inhibitors. J Am Acad Dermatol 2021:S0190-9622(20)32648-7. [PMID: 34332798 DOI: 10.1016/j.jaad.2020.09.054] [Reference Citation Analysis]
5 Schoenberg E, Colombe B, Cha J, Orloff M, Shalabi D, Ross NA, Dasgeb B. Pemphigus associated with ipilimumab therapy. Int J Dermatol 2021;60:e331-3. [PMID: 33410503 DOI: 10.1111/ijd.15405] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]